Proactive And Reactive Phrases, Bamboo Stair Tread Covers, Learn Russian Alphabet, Mezzetta Hot Chili Peppers Scoville Scale, The Nugget Spot Nyc Menu, Zenith Flare Counter, Moorhead Volleyball Roster, Vegetarian Split Pea And Vegetable Soup, Hawaiian Cosmopolitan Recipe, What Are The Largest Black Holes Called, Chipolo One Review, " />

patheon thermo fisher acquisition

Elk Grove Divorce Attorney - Robert B. Anson

patheon thermo fisher acquisition

On August 29, 2017, Thermo Fisher Scientific completed its acquisition of Patheon for $7.2 billion. In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted earnings per share (EPS) and adjusted operating income, which exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; and amortization of acquisition-related intangible assets. and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. Process Development, Validation & Scale Up, Starting Materials, Intermediates & API Sourcing, Clinical Batch Supply (Phase I, II & III), Clinical Batch Supply (Phase I, II, & III), Pre-Clinical & Clinical cGMP Manufacturing, Commercial Process Characterization & Validation, Project Management & Supply Chain Leaders, Investigator Initiated Trial (IIT) Supply Chain Management, ProSyries Pre-Filled Syringe Assembly & Labeling, Starting Materials, Intermediates, & API Sourcing. Patheon, by Thermo Fisher Scientific, has state-of-the-art development and manufacturing facilities throughout North America, Europe and Australia. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the expiration of the subsequent offering period of its previously announced tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. All from the most cited life science brands. Thermo Fisher’s shopping spree continues with $5.2B acquisition of Patheon The king of life science acquisitions has struck again. Delisting is likely to reduce significantly the liquidity and marketability of any Patheon ordinary shares that have not been tendered pursuant to the tender offer. In addition, investors and shareholders of Patheon may obtain free copies of the tender offer materials by contacting D.F. Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, just weeks after Lonza completed its $5.5 billion buyout of capsule maker Capsugel. Thermo Fisher's wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., has accepted for payment all shares that were validly tendered and were not properly withdrawn as of the Expiration Time, and payment for such shares will be made promptly in accordance with the terms of the offer. Patheon generated fiscal 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher's Laboratory Products and Services Segment. We bring formulation and process development expertise to pursue early-phase goals and establish a scientifically-sound foundation for success in later stages and beyond. Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. 1 Adjusted earnings per share and adjusted operating income are non-GAAP measures that exclude certain items detailed later in the press release under the heading "Use of Non-GAAP Financial Measures. WALTHAM, Mass. © 2020 Thermo Fisher Scientific Inc. All rights reserved. We're delighted to welcome our Patheon colleagues to the Thermo Fisher team and excited about the new opportunities we have to help our customers accelerate innovation and enhance productivity by leveraging our combined strengths.". Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent and pending acquisitions, including the acquisition of Patheon, may not materialize as expected; difficulty retaining key employees; and our ability to successfully implement integration strategies or to achieve expected synergies and operating efficiencies within the expected time-frames or at all. ", Media Contact Information: Karen Kirkwood Phone: 781-622-1306 E-mail:  [email protected]  Website: www.thermofisher.com  or Investor Contact Information: Ken Apicerno Phone: 781-622-1294 E-mail:  [email protected], View original content with multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. Patheon Development services ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. On May 31, 2017, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, was filed with the SEC by Thermo Fisher and its acquisition subsidiary and a solicitation/recommendation statement on Schedule 14D-9 was filed with the SEC by Patheon with respect to the tender offer. The offer to purchase all of the outstanding ordinary shares of Patheon is only being made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today it has completed its $7.2 billion acquisition of contract development and manufacturing organization (CDMO) Patheon. Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Additional Information and Where to Find It. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately … Patheon – end-to-end pharma services solutions for every drug development journey. Brands. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … INVESTORS AND SHAREHOLDERS OF PATHEON ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. "By adding Patheon’s highly complementary CDMO capabilities to our … Patheon does not own any of the licences of the products it manufactures and is often listed as the manufacturer on packaging, with the product licence holder's brand name, product name and corporate … King & Co., Inc., Thermo Fisher's information agent for the tender offer. © Copyright 2016 Thermo Fisher Scientific Inc. All rights reserved. Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash. and DURHAM, N.C., May 15, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. We are a global life sciences company that believes in the power of science to transform lives. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of Patheon or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher and its acquisition subsidiary have filed with the SEC. Thermo Fisher also announced the commencement of a subsequent offering period scheduled to expire at 12:01 a.m., New York City time, on September 13, 2017, as more fully described in the tender offer statement on Schedule TO filed by Thermo Fisher with the U.S. Securities and Exchange Commission (the "SEC") on May 31, 2017 (as amended and supplemented, the "Schedule TO"). On August 29, Thermo Fisher Scientific Inc. completed its acquisition of Patheon N.V., a contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has completed its acquisition of Patheon, a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Patheon has invested significantly to become a scale player in the CDMO market and extend its leadership position. Durham-based Patheon N.V., a global provider of pharmaceutical development and manufacturing services that has a large production facility in Greenville, will be acquired by Thermo Fisher Scientific in a deal worth about $5.2 billion.. Thermo Fisher Completes $7.2B Patheon Acquisition. "We’re pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. Today, Thermo Fisher is acquiring approximately 95.3% of Patheon's outstanding ordinary shares. Goldman Sachs & Co. acted as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. Thermo Fisher said the acquisition of Patheon will provide the company with entry into the attractive and high growth contract development and manufacturing organization market. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. Thermo Fisher Scientific Inc. TMO recently completed the buyout of Patheon N.V. that their boards of directors have approved Thermo Fisher’s acquisition of Patheon. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in Thermo Fisher's Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the SEC and available in the "Investors" section of Thermo Fisher's website, ir.thermofisher.com, under the heading "SEC Filings," and in any subsequent Quarterly Reports on Form 10-Q and other documents Thermo Fisher files with the SEC, and in Patheon's Annual Report on Form 10-K for the year ended October 31, 2016, and its subsequent Quarterly Reports on Form 10-Q, including its Quarterly Report on Form 10-Q for the quarter ended January 31, 2017, and its Quarterly Report on Form 10-Q for the quarter ended April 30, 2017, each of which is on file with the SEC and available in the "Investor Relations" section of Patheon's website, ir.patheon.com, under the heading "SEC Filings," and in other documents Patheon files with the SEC. The board of directors of the two publicly traded companies approved the acquisition in which Thermo Fisher … ... Thermo Fisher Scientific Inc. announces acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation … Details of the 2017 impact will be provided during Thermo Fisher's third quarter earnings call in late October. Thermo Fisher continues to expect to realize total synergies of approximately $120 million by year three following the close, consisting of approximately $90 million of cost synergies and approximately $30 million of adjusted operating income benefit from revenue-related synergies. Morgan Stanley & Co. acted as financial advisor to Patheon, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Aug 29, 2017 | staff reporter. Large Molecule Biologics Commercialization. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. Thermo Fisher Scientific Completes Acquisition of Patheon, Annual Meeting 2020 Questions and Answers, GAAP/Non-GAAP Reconciliation and Financial Package, http://www.prnewswire.com/news-releases/thermo-fisher-scientific-completes-acquisition-of-patheon-300510547.html. "We're pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. The initial offering period for the tender offer and withdrawal rights expired at 5:00 p.m., New York City time, on August 28, 2017 (the "Expiration Time"). Patheon – end-to-end pharma services solutions for every drug development journey ... Thermo Fisher is a trusted partner for every step in the drug development journey with unrivaled quality, reliability, and expertise. Following delisting from the NYSE, Patheon ordinary shares will not be listed or registered on another national securities exchange. To support scientists worldwide, we offer high-quality, innovative solutions—from everyday essentials to instruments—for every lab, every application. and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that … Our mission is to enable our customers to make the world healthier, cleaner and safer. Adjusted EPS also excludes certain other gains and losses that are either isolated or cannot be expected to occur again with any regularity or predictability, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and the results of discontinued operations. In August 2017, Thermo Fisher Scientific completed the acquisition of Patheon, creating the world’s most comprehensive and sophisticated end-to-end CDMO partner. Thermo Fisher Scientific provides industry leading CDMO services as well as clinical trial solutions. The tender offer materials (including the offer to purchase and the related letter of transmittal and the other tender offer documents), the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Patheon may be obtained free of charge at the SEC's website at www.sec.gov or at Patheon's website at www.patheon.com or by contacting Patheon's investor relations department at 919-226-3165 or at Thermo Fisher's website at www.thermofisher.com or by contacting Thermo Fisher's investor relations department at 781-622-1111. For the remainder of 2017, the transaction is expected to be approximately $0.09 accretive to adjusted earnings per share1, which includes $0.02 in the third quarter. Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher … Our Fisher Clinical Services SM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Words such as "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed to be forward-looking statements. All ordinary shares validly tendered during the subsequent offering period will be immediately accepted for payment, and tendering holders will thereafter promptly be paid the same form and amount of offer consideration as in the initial offering period. Announcement of the deal resulted in increases in Thermo Fisher and Patheon shares by 0.5% and 33.2%, respectively. For more information, please visit www.thermofisher.com. Patheon. Brands. The tender offer referenced herein commenced on May 31, 2017. WALTHAM, Mass. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. The procedures for tendering shares during the subsequent offering period are described in the Schedule TO and are generally the same as those applicable to the initial offering period, except that the guaranteed delivery procedures may not be used during the subsequent offering period and no withdrawal rights will apply to shares tendered during the subsequent offering period. Patheon also intends to terminate its reporting obligations under the Exchange Act by filing a Form 15 with the SEC on or about September 11, 2017. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion . Patheon, by Thermo Fisher Scientific, is a leading drug Contract Development & Manufacturing Organization (CDMO) serving more than 400 pharmaceutical clients worldwide. Dosage Forms, Products. The timing and amount of these items are uncertain and could be material to Thermo Fisher's results computed in accordance with GAAP. The close follows the expiration of Thermo Fisher’s initial tender offer for Patheon … Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical … The company completed the acquisition of Patheon on August 29, … Thermo Fisher does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. Thermo Fisher also anticipates saving approximately $120 million by the third year after completion of the acquisition. WALTHAM, Mass. Today's close follows the expiration of Thermo Fisher… In this webinar, Thermo Fisher … Patheon is your end-to-end viral vector CDMO partner from process and analytical development to clinical and commercial supply for your cell or gene therapy or vaccine. About Patheon. Thermo Fisher Scientific provides industry leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers of all sizes through our Patheon brand. Thermo Fisher Scientific is acquiring Patheon, which has been at the center of the consolidation that has swept through contract manufacturing in recent years, in a deal valued at $7.2 billion. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. This press release contains forward-looking statements that involve a number of risks and uncertainties. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Thermo Fisher to acquire Patheon $7.2 billion purchase of contract drug maker opens a new business front for the instrument firm by Marc S. Reisch May 17, 2017 | APPEARED IN VOLUME 95, ISSUE 21 With … The transaction represents a purchase price of approximately $7.2 billion, which includes In this webinar, Thermo Fisher senior executives, Franco Negron and Leon Wyszkowski, provide an inside view of how Pharma Services is redefining outsourced biopharmaceutical services. One year later, Thermo Fisher’s Pharma Services is delivering integrated drug development and clinical trial services to clients across the globe. "By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers. WALTHAM, Mass., Aug. 29, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Based on information provided by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 138,406,058 Patheon ordinary shares, representing approximately 95.3% of the outstanding Patheon ordinary shares, had been validly tendered and had not been properly withdrawn as of the Expiration Time (excluding 176,509 ordinary shares, representing approximately 0.12% of the aggregate number of ordinary shares outstanding, tendered pursuant to guaranteed delivery procedures that have not yet been delivered in settlement or satisfaction of such guarantee). THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND THE OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 CONTAIN IMPORTANT INFORMATION. Patheon has requested that the New York Stock Exchange (the "NYSE") suspend trading of Patheon ordinary shares after the close of business on September 1, 2017, and Patheon intends to file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") with the SEC on such date. While Thermo Fisher may elect to update forward-looking statements at some point in the future, Thermo Fisher specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing Thermo Fisher's views as of any date subsequent to today. These non-GAAP projections should not be considered a substitute for GAAP measures. Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Thermo Fisher offered $ 7.2 billion for Patheon acquisition (Source: Pixabay) Waltham/USA — The next step will be a tender offer to acquire all of the issued and outstanding shares of Patheon for $ 35.00 per share in cash.

Proactive And Reactive Phrases, Bamboo Stair Tread Covers, Learn Russian Alphabet, Mezzetta Hot Chili Peppers Scoville Scale, The Nugget Spot Nyc Menu, Zenith Flare Counter, Moorhead Volleyball Roster, Vegetarian Split Pea And Vegetable Soup, Hawaiian Cosmopolitan Recipe, What Are The Largest Black Holes Called, Chipolo One Review,